<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10732750</article-id><article-id pub-id-type="pmc">2374380</article-id><article-id pub-id-type="pii">6691003</article-id><article-id pub-id-type="doi">10.1054/bjoc.1999.1003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van Putten</surname><given-names>J W G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eppinga</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Erjavec</surname><given-names>Z</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>de Leede</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nabers</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Smeets</surname><given-names>J B E</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Sleijfer</surname><given-names>D Th</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Groen</surname><given-names>H J M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Pulmonary Diseases and <label>2</label>Medical Oncology, University Hospital, Hanzeplein 1, Groningen, GZ, 9713, The Netherlands</aff><aff id="aff3"><label>3</label>Department of Pulmonary Diseases, Hospital &#x02018;Nij Smellinghe&#x02019;, Drachten, The Netherlands</aff><aff id="aff4"><label>4</label>Department of Internal Medicine, Delfzicht Hospital, Delfzijl, The Netherlands</aff><aff id="aff5"><label>5</label>Department of Pulmonary Diseases, Bethesda Hospital, Hoogeveen, The Netherlands</aff><aff id="aff6"><label>6</label>Department of Pulmonary Diseases, Medical Center, Leeuwarden, The Netherlands</aff><aff id="aff7"><label>7</label>Pharmacia &#x00026; Upjohn, Woerden, The Netherlands</aff><pub-date pub-type="ppub"><month>02</month><year>2000</year></pub-date><volume>82</volume><issue>4</issue><fpage>806</fpage><lpage>811</lpage><history><date date-type="received"><day>09</day><month>06</month><year>1999</year></date><date date-type="rev-recd"><day>16</day><month>09</month><year>1999</year></date><date date-type="accepted"><day>24</day><month>09</month><year>1999</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The aim of the study was to evaluate efficacy and tolerance of epirubicin and gemcitabine as first-line chemotherapy in patients with advanced non-small-cell lung cancer. A phase I study was performed with the combination of escalating doses of epirubicin intravenously on day 1 and a fixed dose of gemcitabine on days 1 and 8 of a 21-day cycle. Eighteen patients were included in the phase I part of the study before the maximum tolerated dose was found. Dose-limiting toxicity was febrile neutropenia. The phase II part of the study was continued with epirubicin 100 mg m<sup>&#x02212;2</sup>on day 1 and gemcitabine 1125 mg m<sup>&#x02212;2</sup>on days 1 and 8 of a 21-day cycle. Forty-three chemotherapy-naive patients were included. The median age of the patients was 60 years (range 26&#x02013;75). Most patients (74&#x00025;) were in stage IV. Granulocytopenia CTC grade 4 occurred in 32.5&#x00025; and thrombocytopenia grade 4 in 11.6&#x00025; of cycles. Febrile neutropenia occurred in six patients. Non-haematological toxicity was mainly mucositis CTC grade 2 and 3 in 35&#x00025; of patients. The tumour response rate was 49&#x00025; (95&#x00025; confidence interval (CI) 35&#x02013;63&#x00025;). The median survival time for the patients was 42 weeks (95&#x00025; CI 13&#x02013;69). &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>non-small-cell lung cancer</kwd><kwd>chemotherapy</kwd><kwd>epirubicin</kwd><kwd>gemcitabine</kwd></kwd-group></article-meta></front></article>


